$CYPH Soars 39.5% as EPS Estimate Revision Drives Healthcare Rally
Cypherpunk Technologies (CYPH) surged 39.5% since September 10 after its next-year EPS growth estimate was revised from 340% to 2900%, dwarfing peer gains. Fossil Group (FOSL) jumped 25.4% on a similar upward revision, while Twist Bioscience (TWST), CrowdStrike (CRWD), and Hyperliquid Strategies (PURR) posted gains of 23.9%, 18.8%, and 16.5%, respectively, as the screener caught early earnings estimate revisions that the market validated with strong price action.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| CYPH | Healthcare | 2026-09-10 | +2560.0pp | +39.5% |
| FOSL | Consumer Cyclical | 2026-09-10 | +664.7pp | +25.4% |
| TWST | Healthcare | 2026-09-09 | +1.5pp | +23.9% |
| CRWD | Technology | 2026-09-13 | N/A | +18.8% |
| PURR | Financial | 2026-09-10 | +6.1pp | +16.5% |
Why did CYPH stock jump in September 2026?
CYPH jumped 39.5% (from $2.20 to $3.07) after analysts raised its next-year EPS growth estimate from 340% to 2900% on September 10.
The dramatic upward revision, though not accompanied by company-specific news, reflects a broader surge in healthcare sector optimism, particularly for companies with innovative technologies. The screener detected this extreme revision early, and the market quickly confirmed it with a sharp price increase, resulting in a 39.5% gain by September 17.
CYPH EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: CYPH
Why did CYPH stock jump?
CYPH stock jumped 39.5% from $2.20 to $3.07 after its next-year EPS growth estimate was revised upward to 2900% on September 10.
Is CYPH a buy after the rally?
The stock's 39.5% rally reflects extreme earnings growth expectations, but without specific news, investors should consider the sustainability of such a high EPS revision.
What is CYPH's EPS growth estimate?
CYPH's next-year EPS growth estimate is 2900%, up from 340% before the revision on September 10.
Why did FOSL stock jump in September 2026?
FOSL surged 25.4% (from $4.49 to $5.63) after its next-year EPS growth estimate was revised from 111.5% to 776.2% on September 10.
The upward revision signals improving profitability prospects for the consumer cyclical sector, which has been rebounding on resilient consumer spending. The screener flagged this revision, and the market responded with a strong price gain over the following week.
FOSL EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: FOSL
Why did FOSL stock jump?
FOSL stock jumped 25.4% from $4.49 to $5.63 after its next-year EPS growth estimate was revised upward to 776.2% on September 10.
What caused FOSL's surge?
FOSL's surge was caused by a massive upward revision in its next-year EPS growth estimate, from 111.5% to 776.2%, detected by our screener.
Is FOSL a buy after the rally?
The sharp upward EPS revision suggests strong earnings growth potential, but the 25.4% rally may have priced in much of the optimism; evaluate broader consumer sector trends.
Why did TWST stock jump in September 2026?
TWST gained 23.9% (from $125.52 to $155.56) after its next-year EPS growth estimate was revised from 35.1% to 36.6% on September 9.
Even a modest 1.5 percentage point increase in the estimate was enough to spark a rally, as investors focused on the healthcare sector's growth potential. The screener caught this revision early, and the market pushed the stock higher, reflecting confidence in Twist Bioscience's synthetic biology platform.
TWST EPS revision history → · Screener snapshot from 2026-09-09 →
FAQ: TWST
Why did TWST stock jump?
TWST stock jumped 23.9% from $125.52 to $155.56 after its next-year EPS growth estimate was revised upward to 36.6% on September 9.
What is TWST's EPS growth estimate?
TWST's next-year EPS growth estimate is 36.6%, slightly up from 35.1% before the revision.
Is TWST a buy after the rally?
The stock's 23.9% gain on a small EPS revision suggests strong market sentiment, but investors should assess whether the growth estimate justifies the price move.
Why did CRWD stock jump in September 2026?
CRWD jumped 18.8% (from $206.74 to $245.70) after analysts reaffirmed its next-year EPS growth estimate of 27.5% on September 13, with no change from prior levels.
The move was reinforced by news on September 14 highlighting CrowdStrike CEO George Kurtz's dismissal of an AI slowdown, emphasizing growing cybersecurity opportunities. The screener detected the stable estimate, and the market, buoyed by sector optimism, drove the stock higher.
CRWD EPS revision history → · Screener snapshot from 2026-09-13 →
FAQ: CRWD
Why did CRWD stock jump?
CRWD stock jumped 18.8% from $206.74 to $245.70 after its next-year EPS growth estimate was maintained at 27.5% on September 13, supported by positive AI cybersecurity sentiment.
What caused CRWD's surge?
CRWD's surge was driven by sector optimism after CEO George Kurtz dismissed AI slowdown fears, highlighting cybersecurity demand, as reported on September 14.
Is CRWD a buy after the rally?
The 18.8% rally reflects confidence in CrowdStrike's stable earnings growth and AI-driven cybersecurity opportunities, but the stock's valuation may be stretched after such a move.
Why did PURR stock jump in September 2026?
PURR climbed 16.5% (from $11.01 to $12.83) after its next-year EPS growth estimate was revised from 43.9% to 50.0% on September 10.
The upward revision in the financial sector points to improving profitability, likely driven by favorable market conditions. The screener identified this revision, and the market responded with a solid gain, reflecting confidence in Hyperliquid Strategies' earnings trajectory.
PURR EPS revision history → · Screener snapshot from 2026-09-10 →
FAQ: PURR
Why did PURR stock jump?
PURR stock jumped 16.5% from $11.01 to $12.83 after its next-year EPS growth estimate was revised upward to 50.0% on September 10.
What is PURR's EPS growth estimate?
PURR's next-year EPS growth estimate is 50.0%, up from 43.9% before the revision.
Is PURR a buy after the rally?
The 16.5% gain on a moderate EPS revision suggests investor optimism, but potential buyers should consider the financial sector's broader trends and the stock's valuation.
Today's top performers highlight the market's sensitivity to earnings estimate revisions, particularly in healthcare and technology, where even modest upgrades can trigger significant rallies. This suggests a bullish sentiment focused on companies with improving profitability prospects.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →